Sep 30 |
Andreas Halvorsen's Strategic Acquisition in BioMarin Pharmaceutical Inc
|
Sep 30 |
Andreas Halvorsen's Firm Expands Grip in BioMarin Pharmaceutical Inc Holding
|
Sep 30 |
High Growth Tech Stocks To Watch For Future Potential
|
Sep 25 |
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
|
Sep 24 |
BioMarin Pharmaceutical reaffirms long-term outlook
|
Sep 22 |
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
|
Sep 21 |
BioMarin (BMRN): Strong Results and ROCTAVIAN Progress Make It a Mid-Cap Growth Gem
|
Sep 18 |
BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting
|
Sep 17 |
Ascendis Challenges BioMarin, But Market Response Seems Excessive
|
Sep 17 |
Ascendis Soars on Encouraging Data From Dwarfism Drug Study
|